Therapeutics that target γ-secretase produced different results in human neurons and mouse models of Alzheimer’s disease.
Results suggest the drug boosts cognition when given alongside the acetylcholinesterase inhibitor.
ALS-linked optineurin works closely with Parkinson’s-associated Pink1 and parkin in a pathway that recycles mitochondria.
The pharma giant puts up funding to help develop AstraZeneca’s inhibitor, the second such compound to enter Phase 2 testing.
A study claims that two genetic variants combined may hasten cognitive decline in people who have Aβ deposits in the brain.
A new assay detects tau and α-synuclein seeds in human brain samples. Could it become a diagnostic?
Scientists have published 11 instances of mutations in the mitochondrial protein CHCHD10 that contribute to ALS, ALS-FTD, and myopathy.
Two studies claim that α-synuclein multimers have a physiological role as wranglers of synaptic vesicles. They come to different conclusions on the finer points, but could they fit into one grand model?
In mouse models, removing this growth factor only from immune cells worsened pathology and memory.
People who lose their sense of smell have triple the odds of dying within five years. Some speculate neurodegenerative disease is involved.
Getting a close-up view of nicastrin, scientists find more evidence that this γ-secretase subunit snags substrates for presenilin.
At Birthday Symposium, Massachusetts ADRC Looks to Future With New Data As the first five of the nation’s 27 Alzheimer’s Disease Research Centers system marked their 30th birthday, one of them celebrated with a scientific conference at Massachusetts ...
MGH meeting traces arc of scientific discoveries from 1980s to today’s cutting edge.
Older people who complain of memory problems are more likely to become measurably impaired and to have Alzheimer’s pathology in the brain, especially if they smoke or carry an ApoE4 allele.
Protein oligomers may be to blame in TDP-43 proteinopathies, as in other neurodegenerative conditions.